The Problem:

Cancers of the liver affect 1.2 million globally people every year. Additional treatment options are required for these patients.

Our Solution:

We are investigating a percutaneous targeted, whole-organ therapy that delivers high-dose chemotherapy directly to the liver with blood filtration to reduce systemic toxicity and related side effects (Melphalan/Hepatic Delivery System).

Our Team:

Dedication and commitment to improving patients’ lives